About
Kenson’s biomedical investments focus on molecular tools, diagnostics, and therapeutics. The company prides itself on identifying and partnering with strong, capable management teams operating in niche markets where differentiation, chosen strategies and excellence in execution are keys. A significant percentage of Kenson-backed companies have achieved successful liquidity through mergers and acquisitions, demonstrating the effectiveness of its approach in selecting the right teams for delivering optimal results.
Kenneth Fong, PhD
Chairman
Dr. Kenneth Fong is the Founder & Chairman of Kenson Ventures, LLC. He has spent more than 40 years in the biotech industry after completing his academic pursuit in biomedcal research.
He is best known for founding the biotech company, Clontech in 1984, which he built into one of the largest biomedical tool companies founded by an Asian American in the US (400 employees including 65 PhD scientists). Clontech was aquired by Becton Dickinson in 1999 and Ken continued his career as a venture capitalist with Kenson Ventures LLC, that he started. He has since cultivated a number of highly successful entrepreneurs, advising and working with them on the growth of their companies.
Currently, he sits on the board of 4 biotech companies and he was intimately involved with the M/A and IPO of more than 15 companies that are worth more than $10 billions. These companies range from research tools, medical diagnostics and drug development. In almost all cases, Dr. Fong has been instrumental in providing strategies for sustainable growth, value creation and liquidity. Those successful entrepreneurs have moved on to assume leadership in other start-ups and mid-sized companies, which in turn led to a new generation of entrepreneurs.
Ken obtained his PhD from Indiana University and post-doctoral studies at UCLA & NIH.
